-
12 drugs now in shortage
A quarter of the nation's current drug shortages are more than five years old, and a slight majority are at least two years old. -
Vaccine therapy from Merck, Moderna may cut risk of skin cancer recurrence in half
Results from a phase 2 trial found a drug-vaccine combination developed by Merck and Moderna cut the risk of recurrence or death in patients with severe melanomas by 49%. -
Supreme Court to hear case on mifepristone
The Supreme Court decided Dec. 13 to review a decision from the Fifth Circuit on mifepristone. The outcome could limit access to the abortion drug. -
Poison control centers see surge in calls about weight-loss drugs
In the first 11 months of 2023, poison control centers across the U.S. received nearly 3,000 calls involving semaglutide — a more than 15-fold increase since 2019, according to a Dec. 13 report from CNN. -
AstraZeneca to buy vaccine company for $1.1B
AstraZeneca has entered a definitive agreement to acquire Icosavax for $1.1 billion, the drugmaker said Dec. 12. -
Pharmacies share customer records with police without a warrant: Congressional probe
A congressional probe launched after the Supreme Court's decision in 2022 to overturn Roe v. Wade has found eight of the nation's largest pharmacy chains allow pharmacy staff to share customer records with police and government investigators without a warrant, according to a Dec. 12 report from The Washington Post. -
Optum Rx to offer weight management program
Optum Rx is launching a new weight management and wellness support program for health plan sponsors, including employers, beginning Jan. 1. -
Moderna exec steps down ahead of 2024 product launch plans
Moderna announced Dec. 12 that its chief commercial officer, will step down. The company is planning several commercial product launches in 2024 and 2025, and noted that this strategic reorganization of leadership is an adjustment to help it align with those goals. -
'Unsupported' drug price increases cost payers $1.3B: ICER
Eight drugs had price increases so steep that they cost health insurers nearly $1.3 billion from 2021 to 2022, according to a Dec. 11 report from the Institute for Clinical and Economic Review. -
Pfizer donates rights to cancer drug
Pfizer will donate the royalty rights from sales of cancer drug Bavencio to the American Association for Cancer Research starting in January. -
The street drug alarming physicians that's 10x more potent than fentanyl
Nitazenes, a group of highly potent, synthetic drugs made in the 1950s as opioid analgesics, are becoming more commonly used in street drugs. In some cases, it can even be 10 times more potent than fentanyl. -
Novartis reports success in phase 3 trial of drug for rare kidney disease
Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease. -
9 hospitals cleared to deliver new CRISPR-based sickle cell treatment
The FDA made a historic approval Dec. 8 when it cleared Casgevy, the nation's first medicine based on CRISPR gene-editing technology, as a treatment for sickle cell disease. Its makers are now working with hospitals to establish a network of specialized treatment centers, and so far nine have been authorized to deliver the treatment. -
FDA approves nation's 1st CRISPR gene therapy to treat sickle cell disease: Experts react
On Dec. 8, the FDA approved the nation's first medicine based on CRISPR gene-editing technology to be used as a treatment for patients with sickle cell disease, a major scientific advancement that opens the door for future gene therapy approvals for inherited disorders. -
Walgreens expands testing, treatment options for COVID-19, flu
Walgreens will expand treatment and testing options for COVID-19 and the flu, the company announced Dec. 7. -
Biden administration OKs ability to seize drug patents to lower costs
After a nearly nine-month review, the Biden administration has determined it has the authority to seize the patents of certain high-priced drugs developed with taxpayer funds — a policy known as march-in rights. -
8 most influential drug approvals in 2023: GoodRx
Out of the hundreds of new drugs entering the U.S. market, eight made tailwinds in the healthcare industry, according to GoodRx. -
Adherence to Wegovy far outpaces older weight loss drugs: Cleveland Clinic study
Patients taking Novo Nordisk's weight loss drug Wegovy in 2021 and 2022 were three times more likely to continue taking the medication a year later compared to older weight loss therapies, according to a study published Dec. 6 in Obesity. -
How 2 pharmacy leaders became hospital CEOs
As more systems create a C-suite role for pharmacy leaders, health systems and hospitals are increasingly promoting these executives to non-pharmacy roles, such as CEO. -
Eli Lilly obesity drug hits pharmacy shelves
Zepbound, a newly approved obesity drug from Eli Lilly, hit the market Dec. 5.
Page 15 of 50